Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the activity of ZD1839 250 mg once daily in
addition to the standard chemotherapy in patients with advanced or metastatic transitional
cell carcinoma of the urothelium by estimating the time to progression.